We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GPC Biotech has launched a Phase I study evaluating its lead drug candidate,
satraplatin, in combination with Taxotere (docetaxel) in patients with advanced
solid tumors has opened for accrual.
NeoRx, a cancer therapeutics development company, announced treatment of the
first patient with picoplatin, its next-generation intravenous platinum therapy,
in a Phase II clinical trial in small cell lung cancer.
Amgen has announced new interim data from a Phase II study evaluating the use
of 500 mcg of Aranesp (darbepoetin alfa) every three weeks to treat anemia in
patients with a bone marrow disorder known as myelodysplastic syndromes (MDS).
Sonus has announced that the FDA has completed a Special Protocol Assessment
(SPA) for the pivotal Phase III trial of the company's lead cancer product candidate,
Tocosol Paclitaxel.
A story in the June 29 issue of
FDAnews Drug Pipeline Alert should have stated that Baxter Pharmaceutical Solutions in Bloomington, Ind., would fill and package Viprinex for Neurobiological
Technologies.
Pro-Pharmaceuticals, a developer of cancer therapeutics to target cancer cells
through carbohydrate chemistry, has been awarded a new patent from the U.S.
Patent & Trademark Office titled "Delivery of a Therapeutic Agent in
a Formulation for Reduced Toxicity."
The FDA has tentatively approved Aurobindo Pharma's generic version of Bristol-Myers
Squibb's HIV-1 treatment Zerit (stavudine) capsules. Hyderabad, India-based
Aurobindo is the first company to receive tentative approval for generic Zerit.
AstraZeneca announced the publication of results from a large-scale clinical
study that examined its psychotropic medication Seroquel (quetiapine fumarate)
as a treatment for depressive episodes in patients with bipolar I and II disorders.